Paulette: Announcement of Resolutions of the Third Meeting of the Ninth Board of Directors
Securities code: 300246 Securities abbreviation: Baolai Announcement number: 2025-063 Bond code: 123065 Bond abbreviation: Baolai convertible bonds
Guangdong Baolaite Medical Technology Co., Ltd.
Announcement of Resolutions of the Third Meeting of the Ninth Board of Directors
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions.
Guangdong Baolaite Medical Technology Co., Ltd. (hereinafter referred to as the "Company") held the third meeting of the ninth board of directors on September 30, 2025, using a combination of communication voting and on-site meetings. The meeting notice was delivered by email, phone and fax on September 26, 2025. The company's board of directors has nine directors and nine directors participated in the voting, which is in compliance with the provisions of the Company Law and the Articles of Association.
The meeting was chaired by Mr. Yan Jinyuan, chairman of the company. After voting, the following proposals were reviewed and approved:
1. The "Proposal on Not Revising the Conversion Price of "Baolai Convertible Bonds" Downward" was reviewed and approved.
According to the relevant provisions of the "Prospectus for the GEM Issuance of Convertible Corporate Bonds to Unspecified Targets by Guangdong Baolaite Medical Technology Co., Ltd." (hereinafter referred to as the "Prospectus"), as of September 30, 2025, the closing price of the company's stock on at least fifteen trading days out of any thirty consecutive trading days is lower than 90% of the current conversion price.
The company's board of directors comprehensively considers the company's current basic situation, stock price trends, market environment and other factors, as well as its confidence in the company's long-term stable development and intrinsic value. In order to clarify investor expectations and safeguard the interests of all investors, after careful discussion and deliberation by all directors, it is agreed that the company will not revise the "Baolai Convertible Bonds" conversion price downward this time. 8), if the downward revision clause of the stock conversion price is triggered again, no downward revision plan will be proposed. Starting from December 9, 2025, if the downward revision clause of the conversion price of "Baolai Convertible Bonds" is triggered again, the company will convene a board meeting to consider whether to exercise the right to downward revision of the conversion price of "Baolai Convertible Bonds".
For details, please refer to the "Announcement on Not Revising the Conversion Price of "Baolai Convertible Bonds" Downward" published on the GEM Information Disclosure Website designated by the China Securities Regulatory Commission on the same day.
Securities code: 300246 Securities abbreviation: Baolai Announcement number: 2025-063 Bond code: 123065 Bond abbreviation: Baolai convertible bonds
(9 votes in favor of the above motion, 0 abstentions, and 0 votes against)
Announcement is hereby made.
Board of Directors of Guangdong Baolaite Medical Technology Co., Ltd.
September 30, 2025